Contemporary OB/GYN week in review: mifepristone, HPV vaccine, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: mifepristone, HPV vaccine, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, December 11 - Friday, December 15, 2023), and click each link to read and watch anything you may have missed.
1.) Supreme Court to decide access on mifepristone for abortion
The Supreme Court's upcoming decision on mifepristone, a key abortion medication, may alter access, introducing potential restrictions and impacting the landscape of abortion rights.
Click here for the full article.
2.) How COVID-19 impacted HPV vaccination rates in New York City and Long Island
A recent study looks at the impact COVID-19 had on human papillomavirus vaccination rates in New York City and Long Island.
Click here for the full article.
3.) Elevated bilateral salpingo-oophorectomy rates in women with disabilities
A recent study reveals heightened rates of concomitant bilateral salpingo-oophorectomy during benign hysterectomy in women with disabilities, shedding light on potential disparities and urging improved physician counseling and shared decision-making strategies.
Click here for the full article.
4.) Managing skin health in women
Toby Maurer, MD, professor at University of California, San Francisco, discusses common skin conditions seen in female patients, along with the best methods of treating these conditions.
Click here for the full article.
5.) Evaluating efficacy of active surveillance for CIN2
Discover how active surveillance, a growing approach in managing cervical intraepithelial neoplasia, offers a nuanced alternative to immediate interventions, showcasing promising regression rates and reduced risk of overtreatment.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More
